25 XP   0   0   10

AngioSoma Inc
Buy, Hold or Sell?

Let's analyse AngioSoma Inc together

PenkeI guess you are interested in AngioSoma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AngioSoma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about AngioSoma Inc

I send you an email if I find something interesting about AngioSoma Inc.

Quick analysis of AngioSoma Inc (30 sec.)










What can you expect buying and holding a share of AngioSoma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$0.00
How sure are you?
45.7%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-20.5%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0004 - $0.0007
How sure are you?
50%

1. Valuation of AngioSoma Inc (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.01 - $0.00

Total Value Per Share

$-0.01 - $0.00

2. Growth of AngioSoma Inc (5 min.)




Is AngioSoma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.4m-$1.1m-$249k-18.3%

How much money is AngioSoma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$537.5k-$353.5k-$183.9k-34.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of AngioSoma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#876 / 1001

Most Revenue
#941 / 1001

Most Profit
#212 / 1001

Most Efficient
#354 / 1001

What can you expect buying and holding a share of AngioSoma Inc? (5 min.)

Welcome investor! AngioSoma Inc's management wants to use your money to grow the business. In return you get a share of AngioSoma Inc.

What can you expect buying and holding a share of AngioSoma Inc?

First you should know what it really means to hold a share of AngioSoma Inc. And how you can make/lose money.

Speculation

The Price per Share of AngioSoma Inc is $0.0006. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AngioSoma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AngioSoma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AngioSoma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-50.2%0.00-76.5%0.00-47.3%0.00-103.7%0.00-434.2%
Usd Book Value Change Per Share0.000.0%0.00-8.6%0.00-16.8%0.00-4.0%0.00-6.9%
Usd Dividend Per Share0.0013.8%0.003.4%0.003.4%0.0012.8%0.00159.8%
Usd Total Gains Per Share0.0013.8%0.00-5.1%0.00-13.3%0.008.8%0.00152.9%
Usd Price Per Share0.00-0.00-0.01-0.01-0.84-
Price to Earnings Ratio-0.75--4.15--9.51--166.60--108,450.24-
Price-to-Total Gains Ratio10.87-73.91-40.30--2.35--3,674.40-
Price to Book Ratio-0.73--3.13--7.47--21.63--3,379.65-
Price-to-Total Gains Ratio10.87-73.91-40.30--2.35--3,674.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0006
Number of shares1666666
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (1666666 shares)-51.1988.11
Gains per Year (1666666 shares)-204.76352.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1138-343-215514-161342
2276-685-4201028-323694
3414-1028-6251541-4841046
4552-1371-8302055-6451398
5690-1714-10352569-8071750
6828-2056-12403083-9682102
7966-2399-14453597-11302454
81104-2742-16504110-12912806
91241-3084-18554624-14523158
101379-3427-20605138-16143510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.035.00.00.0%0.046.00.00.0%
Book Value Change Per Share1.02.01.025.0%3.06.03.025.0%8.09.03.040.0%13.019.03.037.1%19.024.03.041.3%
Dividend per Share1.00.03.025.0%2.00.010.016.7%3.00.017.015.0%7.00.028.020.0%7.00.039.015.2%
Total Gains per Share2.02.00.050.0%5.06.01.041.7%10.09.01.050.0%16.018.01.045.7%22.023.01.047.8%

Fundamentals of AngioSoma Inc

About AngioSoma Inc

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

Fundamental data was last updated by Penke on 2024-05-16 20:20:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of AngioSoma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit AngioSoma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AngioSoma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-21,224.4%+21,224.4%
5Y-21,224.4%10Y-14,844.0%-6,380.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--174.3%+174.3%
TTM--210.4%+210.4%
YOY--266.3%+266.3%
5Y-21,224.4%-408.9%-20,815.5%
10Y-14,844.0%-552.3%-14,291.7%
1.1.2. Return on Assets

Shows how efficient AngioSoma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • -199,189.8% Return on Assets means that AngioSoma Inc generated $-1,991.90 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AngioSoma Inc:

  • The MRQ is -199,189.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -305,436.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-199,189.8%TTM-305,436.1%+106,246.3%
TTM-305,436.1%YOY-269,046.5%-36,389.6%
TTM-305,436.1%5Y-123,232.6%-182,203.5%
5Y-123,232.6%10Y-70,639.6%-52,592.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-199,189.8%-11.9%-199,177.9%
TTM-305,436.1%-11.6%-305,424.5%
YOY-269,046.5%-11.0%-269,035.5%
5Y-123,232.6%-13.1%-123,219.5%
10Y-70,639.6%-14.4%-70,625.2%
1.1.3. Return on Equity

Shows how efficient AngioSoma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means AngioSoma Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AngioSoma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-65.4%+65.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.3%+15.3%
TTM--14.7%+14.7%
YOY--13.6%+13.6%
5Y--17.7%+17.7%
10Y-65.4%-19.2%-46.2%

1.2. Operating Efficiency of AngioSoma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient AngioSoma Inc is operating .

  • Measures how much profit AngioSoma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AngioSoma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-22,404.9%+22,404.9%
5Y-22,404.9%10Y-14,446.0%-7,958.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--332.1%+332.1%
TTM--220.9%+220.9%
YOY--281.8%+281.8%
5Y-22,404.9%-408.0%-21,996.9%
10Y-14,446.0%-521.7%-13,924.3%
1.2.2. Operating Ratio

Measures how efficient AngioSoma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AngioSoma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y223.172-223.172
5Y223.17210Y144.261+78.912
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.003-3.003
TTM-3.246-3.246
YOY-3.619-3.619
5Y223.1725.190+217.982
10Y144.2616.874+137.387

1.3. Liquidity of AngioSoma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if AngioSoma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AngioSoma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.0000.000
TTM0.000YOY0.004-0.004
TTM0.0005Y0.070-0.070
5Y0.07010Y0.115-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.814-3.814
TTM0.0004.158-4.158
YOY0.0045.253-5.249
5Y0.0706.098-6.028
10Y0.1156.434-6.319
1.3.2. Quick Ratio

Measures if AngioSoma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AngioSoma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.0000.000
TTM0.000YOY0.001-0.001
TTM0.0005Y0.052-0.052
5Y0.05210Y3.752-3.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.246-3.246
TTM0.0003.837-3.837
YOY0.0015.195-5.194
5Y0.0525.929-5.877
10Y3.7526.351-2.599

1.4. Solvency of AngioSoma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of AngioSoma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AngioSoma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 8,146.94 means that AngioSoma Inc assets are financed with 814,693.8% credit (debt) and the remaining percentage (100% - 814,693.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AngioSoma Inc:

  • The MRQ is 8,146.938. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 7,721.166. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ8,146.938TTM7,721.166+425.771
TTM7,721.166YOY20,665.757-12,944.591
TTM7,721.1665Y5,694.507+2,026.659
5Y5,694.50710Y3,258.845+2,435.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8,146.9380.344+8,146.594
TTM7,721.1660.342+7,720.824
YOY20,665.7570.279+20,665.478
5Y5,694.5070.366+5,694.141
10Y3,258.8450.380+3,258.465
1.4.2. Debt to Equity Ratio

Measures if AngioSoma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AngioSoma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AngioSoma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.708-0.708
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.415-0.415
YOY-0.353-0.353
5Y-0.446-0.446
10Y0.7080.469+0.239

2. Market Valuation of AngioSoma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings AngioSoma Inc generates.

  • Above 15 is considered overpriced but always compare AngioSoma Inc to the Biotechnology industry mean.
  • A PE ratio of -0.75 means the investor is paying $-0.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AngioSoma Inc:

  • The EOD is -0.498. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.746. Based on the earnings, the company is expensive. -2
  • The TTM is -4.153. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.498MRQ-0.746+0.249
MRQ-0.746TTM-4.153+3.407
TTM-4.153YOY-9.513+5.360
TTM-4.1535Y-166.597+162.444
5Y-166.59710Y-108,450.241+108,283.644
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.498-2.359+1.861
MRQ-0.746-2.548+1.802
TTM-4.153-2.742-1.411
YOY-9.513-3.936-5.577
5Y-166.597-6.316-160.281
10Y-108,450.241-6.544-108,443.697
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AngioSoma Inc:

  • The EOD is -2.400. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.599. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -20.171. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.400MRQ-3.599+1.200
MRQ-3.599TTM-20.171+16.572
TTM-20.171YOY-43.240+23.069
TTM-20.1715Y-35.372+15.201
5Y-35.37210Y-764,882.861+764,847.488
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.400-3.091+0.691
MRQ-3.599-3.283-0.316
TTM-20.171-3.529-16.642
YOY-43.240-5.188-38.052
5Y-35.372-8.080-27.292
10Y-764,882.861-8.660-764,874.201
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of AngioSoma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.73 means the investor is paying $-0.73 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AngioSoma Inc:

  • The EOD is -0.487. Based on the equity, the company is expensive. -2
  • The MRQ is -0.730. Based on the equity, the company is expensive. -2
  • The TTM is -3.126. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.487MRQ-0.730+0.243
MRQ-0.730TTM-3.126+2.396
TTM-3.126YOY-7.474+4.347
TTM-3.1265Y-21.632+18.506
5Y-21.63210Y-3,379.646+3,358.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.4872.094-2.581
MRQ-0.7302.032-2.762
TTM-3.1262.065-5.191
YOY-7.4742.688-10.162
5Y-21.6323.692-25.324
10Y-3,379.6464.085-3,383.731
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of AngioSoma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0000%0.0000%0.0000%0.0000%
Book Value Per Share---0.001-0.001-5%-0.001-23%-0.001-38%-0.001-22%
Current Ratio---0.000-100%0.004-100%0.070-100%0.115-100%
Debt To Asset Ratio--8146.9387721.166+6%20665.757-61%5694.507+43%3258.845+150%
Debt To Equity Ratio----0%-0%-0%0.708-100%
Dividend Per Share--0.0000.000+300%0.000+300%0.000+7%0.001-91%
Eps--0.0000.000+52%0.000-6%-0.001+106%-0.003+764%
Free Cash Flow Per Share--0.0000.000-18%0.000-19%0.000+43%0.000+284%
Free Cash Flow To Equity Per Share---0.0000%0.0000%0.000-100%0.0000%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.090-8%
Intrinsic Value_10Y_max---0.004--------
Intrinsic Value_10Y_min---0.008--------
Intrinsic Value_1Y_max--0.000--------
Intrinsic Value_1Y_min---0.001--------
Intrinsic Value_3Y_max---0.001--------
Intrinsic Value_3Y_min---0.003--------
Intrinsic Value_5Y_max---0.002--------
Intrinsic Value_5Y_min---0.004--------
Market Cap697751.962-50%1046627.9424099292.774-74%8402096.538-88%13501500.457-92%982250880.629-100%
Net Profit Margin----0%-0%-212.2440%-148.4400%
Operating Margin----0%-0%-224.0490%-144.4600%
Operating Ratio----0%-0%223.172-100%144.261-100%
Pb Ratio-0.487+33%-0.730-3.126+328%-7.474+924%-21.632+2863%-3379.646+462848%
Pe Ratio-0.498+33%-0.746-4.153+456%-9.513+1175%-166.597+22221%-108450.241+14530311%
Price Per Share0.001-50%0.0010.004-74%0.007-88%0.012-92%0.841-100%
Price To Free Cash Flow Ratio-2.400+33%-3.599-20.171+460%-43.240+1101%-35.372+883%-764882.861+21250301%
Price To Total Gains Ratio7.249-50%10.87473.912-85%40.298-73%-2.351+122%-3674.402+33891%
Quick Ratio---0.000-100%0.001-100%0.052-100%3.752-100%
Return On Assets---1991.898-3054.361+53%-2690.465+35%-1232.326-38%-706.396-65%
Return On Equity----0%-0%-0%-0.6540%
Total Gains Per Share--0.0000.000+137%0.000+197%0.000+57%0.001-91%
Usd Book Value---1433685.000-1358749.250-5%-1109741.250-23%-889325.000-38%-1199128.086-16%
Usd Book Value Change Per Share---0.0000%0.0000%0.0000%0.0000%
Usd Book Value Per Share---0.001-0.001-5%-0.001-23%-0.001-38%-0.001-22%
Usd Dividend Per Share--0.0000.000+300%0.000+300%0.000+7%0.001-91%
Usd Eps--0.0000.000+52%0.000-6%-0.001+106%-0.003+764%
Usd Free Cash Flow---72695.000-59828.250-18%-59150.500-19%-103754.900+43%-310916.955+328%
Usd Free Cash Flow Per Share--0.0000.000-18%0.000-19%0.000+43%0.000+284%
Usd Free Cash Flow To Equity Per Share---0.0000%0.0000%0.000-100%0.0000%
Usd Market Cap697751.962-50%1046627.9424099292.774-74%8402096.538-88%13501500.457-92%982250880.629-100%
Usd Price Per Share0.001-50%0.0010.004-74%0.007-88%0.012-92%0.841-100%
Usd Profit---350574.000-537567.500+53%-353587.250+1%-925885.550+164%-989197.713+182%
Usd Revenue----0%-0%252.550-100%1874939.314-100%
Usd Total Gains Per Share--0.0000.000+137%0.000+197%0.000+57%0.001-91%
 EOD+1 -7MRQTTM+9 -16YOY+8 -175Y+13 -1610Y+10 -19

3.2. Fundamental Score

Let's check the fundamental score of AngioSoma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.498
Price to Book Ratio (EOD)Between0-1-0.487
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.000
Debt to Asset Ratio (MRQ)Less than18,146.938
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1,991.898
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of AngioSoma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.823
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.001
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets0
Total Liabilities1,434
Total Stockholder Equity-1,434
 As reported
Total Liabilities 1,434
Total Stockholder Equity+ -1,434
Total Assets = 0

Assets

Total Current Assets
Total Current Assets  (as reported)0
Total Current Assets  (calculated)0
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,434
Long-term Liabilities0
Total Stockholder Equity-1,434
Total Current Liabilities
Short-term Debt 360
Short Long Term Debt 369
Accounts payable 328
Other Current Liabilities 746
Total Current Liabilities  (as reported)1,434
Total Current Liabilities  (calculated)1,803
+/- 369
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock996
Retained Earnings -20,454
Other Stockholders Equity 18,023
Total Stockholder Equity (as reported)-1,434
Total Stockholder Equity (calculated)-1,435
+/- 1
Other
Capital Stock1,051
Common Stock Shares Outstanding 996,120
Current Deferred Revenue-102
Net Debt 360
Net Invested Capital -1,165
Net Working Capital -1,533
Short Long Term Debt Total 360



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-06-302016-03-312015-12-312015-06-302015-03-312014-12-312014-06-302014-03-312013-12-312013-06-302013-03-312012-12-312012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-31
> Total Assets 
5
3
48
22
1
263
283
282
409
570
463
412
425
478
461
356
322
312
3,252
15
24
370,807
25
88
131
125
139
159
142
93
77
93
90
70
159
20
6
6
1
0
10
10
0
0
0
0
0000101001662015970909377931421591391251318825370,80724153,2523123223564614784254124635704092822832631224835
   > Total Current Assets 
5
3
48
22
1
57
2
1
48
210
138
113
52
29
21
15
11
46
14
1
12
75,149
15
75
116
112
127
146
141
92
76
92
89
69
159
20
6
6
1
0
10
10
0
0
0
0
000010100166201596989927692141146127112116751575,149121144611152129521131382104812571224835
       Cash And Cash Equivalents 
5
3
48
22
1
57
2
1
34
204
128
91
18
1
3
3
6
39
9
0
11
29,229
14
67
112
92
84
105
100
49
33
50
81
66
159
20
6
6
1
0
6
6
0
0
0
0
00006601662015966815033491001058492112671429,229110939633118911282043412571224835
       Net Receivables 
0
0
0
0
0
0
0
24
14
6
10
22
22
16
6
12
5
6
4
6
4
40,353
38,575
22,148
18,156
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000018,15622,14838,57540,3534646512616222210614240000000
       Other Current Assets 
0
0
0
0
0
0
0
24
14
0
5
0
12
12
12
0
1
2
1
1
1
4,400
1
8
0
16
2
2
1
3
2
2
5
0
0
0
0
4
0
0
0
0
0
0
0
0
00000000400005223122160814,40011121012121205014240000000
   > Long-term Assets 
0
0
0
0
0
206
281
281
360
360
324
298
373
448
440
341
311
265
3,238
14
12
0
10
14
15
13
13
13
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
000000000000111111131313151410012143,23826531134144044837329832436036028128120600000
       Property Plant Equipment 
0
0
0
0
0
206
281
281
360
360
324
298
317
396
385
288
255
236
234
0
0
294,367
325,095
252,660
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001111111111252,660325,095294,3670023423625528838539631729832436036028128120600000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,991
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000002,991000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,291
857
601
104
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001046018571,291000000000000000000000
> Total Liabilities 
1
1
26
32
79
444
551
388
380
493
217
566
505
582
615
578
310
539
713
894
1,110
391,583
649
874
901
995
983
887
828
710
682
715
749
759
543
649
732
732
1,084
966
1,204
1,204
1,291
1,277
1,434
1,434
1,4341,4341,2771,2911,2041,2049661,084732732649543759749715682710828887983995901874649391,5831,11089471353931057861558250556621749338038855144479322611
   > Total Current Liabilities 
1
1
26
32
79
444
551
358
349
442
121
369
253
561
539
388
247
494
663
753
928
53,253
505
733
832
995
983
887
828
710
682
715
749
759
543
649
732
732
1,084
966
1,204
1,204
1,291
1,277
1,434
1,434
1,4341,4341,2771,2911,2041,2049661,08473273264954375974971568271082888798399583273350553,25392875366349424738853956125336912144234935855144479322611
       Short-term Debt 
0
0
25
28
70
424
525
329
241
0
1,048
204
57
248
169
93
66
260
404
407
485
333,593
20
117
131
285
260
171
114
116
91
113
155
155
119
89
0
106
20
20
0
20
60
16
0
360
3600166020020201060891191551551139111611417126028513111720333,5934854074042606693169248572041,048024132952542470282500
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
333,593
342,952
352,758
362,752
0
0
0
0
0
0
173
215
215
179
148
166
327
20
20
20
20
0
16
360
369
36936016020202020327166148179215215173000000362,752352,758342,952333,593000000000000000000000
       Accounts payable 
0
0
0
4
9
20
27
29
108
55
114
362
189
294
355
252
131
178
143
135
176
11,411
137
145
144
137
144
138
135
133
133
133
133
144
139
218
342
223
226
221
381
381
450
488
328
328
32832848845038138122122622334221813914413313313313313513814413714414513711,4111761351431781312523552941893621145510829272094000
       Other Current Liabilities 
1
1
1
28
70
424
525
329
241
387
8
8
8
19
16
43
50
56
115
211
267
19,680
348
471
557
573
579
577
579
461
458
468
461
460
286
343
146
403
838
666
60
804
781
41
0
746
7460417818046066683840314634328646046146845846157957757957355747134819,68026721111556504316198883872413295254247028111
   > Long-term Liabilities 
0
0
25
4
9
20
27
31
31
51
96
197
252
21
76
191
63
45
51
140
182
0
144
141
69
422
404
309
249
249
224
247
289
299
258
306
0
329
246
241
0
1
528
0
0
0
0005281024124632903062582992892472242492493094044226914114401821405145631917621252197965131312720942500
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,737
7,413
5,650
6,613
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000006,6135,6507,4134,737000000000000000000000
> Total Stockholder Equity
5
3
23
-10
-78
-181
-269
-106
28
78
245
-154
-80
-104
-154
-222
13
-228
2,539
-879
-1,087
-20,838
-624
-786
-769
-871
-843
-728
-685
-617
-605
-621
-659
-689
-384
-629
-726
-726
-1,083
-966
-1,195
-1,195
-1,291
-1,277
-1,434
-1,434
-1,434-1,434-1,277-1,291-1,195-1,195-966-1,083-726-726-629-384-689-659-621-605-617-685-728-843-871-769-786-624-20,838-1,087-8792,539-22813-222-154-104-80-1542457828-106-269-181-78-102335
   Common Stock
1
1
1
1
1
1
1
1
1
1
1
1
2
3
3
0
9
10
32
37
41
219
46
55
61
69
100
109
170
210
304
383
436
455
476
477
561
561
606
684
722
722
780
872
0
996
9960872780722722684606561561477476455436383304210170109100696155462194137321090332111111111111
   Retained Earnings -20,454-20,454-20,103-18,821-18,505-18,505-18,196-18,038-17,017-17,017-12,754-8,236-7,340-7,215-7,041-6,953-6,835-6,674-6,518-6,517-5,999-5,778-5,687-5,182-838,684-4,197-3,819-84-4,860-4,442-4,153-3,887-3,357-3,141-2,674-2,112-1,675-1,497-1,145-950-228-125-56-24-6-4
   Capital Surplus 0000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
8
8
45
45
45
45
680
1,038
1,525
1,752
2,356
2,518
3,038
3,232
3,709
3,913
4,424
4,627
-395
-91
77
0
1,521
1,851
1,953
2,065
2,580
2,688
5,818
6,007
6,043
6,037
6,120
6,195
7,376
11,648
500
15,730
16,347
16,544
5
16,581
16,723
17,920
0
18,023
18,023017,92016,72316,581516,54416,34715,73050011,6487,3766,1956,1206,0376,0436,0075,8182,6882,5802,0651,9531,8511,521077-91-3954,6274,4243,9133,7093,2323,0382,5182,3561,7521,5251,0386804545454588



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.